Research programme: brain cancer stem cell therapeutics - Loma/NeuralstemAlternative Names: HNSC - Neuralstem; NSI 566 - Loma/Neuralstem; NSI-566 - Glioblastoma
Latest Information Update: 17 May 2013
At a glance
- Originator Neuralstem
- Developer Loma Linda University Medical Center; Neuralstem
- Class Stem cell therapies
- Mechanism of Action Angiogenesis inhibitors; Cell death stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma